Substance / Medication

Loracarbef

Overview

Active Ingredient
loracarbef
RxNorm CUI
28981

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

4 trials linked to this intervention

4
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A systematic review and meta-analysis of the efficacy of platelet-rich plasma products for treatment of equine joint disease.
Peng Cong, Yang Luo, Labens Raphael et al. · Equine Vet J · 2024
PMID: 38185481Meta-Analysis
Variation in Defining Retention After Onabotulinum Toxin A for Overactive Bladder: A Systematic Review.
Castaneda Peris R, Chen Andrew, Kuhlmann Paige et al. · Urogynecology (Phila) · 2024
PMID: 38465990Meta-Analysis
Active Compared With Passive Voiding Trials After Midurethral Sling Surgery: A Systematic Review.
Drangsholt Siri, Lleras Cassidy, Kindler Rebecca et al. · Obstet Gynecol · 2024
PMID: 38547487Meta-Analysis
Surgical arthrolysis of the stiff elbow: a systematic review.
Lanzerath Fabian, Wegmann Kilian, Hackl Michael et al. · Arch Orthop Trauma Surg · 2023
PMID: 35482109Meta-AnalysisFull text (PMC)
Twice-daily dosing of loracarbef 15 mg/kg versus 30 mg/kg in the treatment of children with acute sinusitis.
Balatsouras D G, Korres S, Rallis E et al. · Drugs Exp Clin Res · 2005
PMID: 16444905RCT
Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia.
Aljitawi O S, Krishnan K, Curtis B R et al. · Am J Hematol · 2003
PMID: 12701119Case Report
Assessment of the susceptibility of Streptococcus pneumoniae to cefaclor and loracarbef in 13 countries.
Bandak S I, Turnak M R, Allen B S et al. · J Chemother · 2000
PMID: 10949979Other
Penicillin V, loracarbef and clindamycin in tonsillar surface fluid during acute group A streptococcal pharyngotonsillitis.
Orrling Arne, Kamme Carl, Stjernquist-Desatnik Anna · Scand J Infect Dis · 2005
PMID: 16012002Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Loracarbef (substance)
SNOMED CT
96061006
UMLS CUI
C0065295
RxNorm CUI
28981

Clinical Data

This intervention maps to 8 entities in the Healos knowledge graph.

8
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
4
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.